Glucotrack, Inc.GCTK

Glucotrack Inc., the New Jersey-based outfit pitching an implantable continuous glucose monitor (CGM) with a 12-month sensor life, filed its March 2026 quarterly report on 17 July 2026 and the numbers are the kind that make even the most optimistic CGM cheerleader pause. For the three months to 31 March 2026, the company posted a net loss attributable to parent of $4.3m against $3.9m in cash and cash equivalents, leaving shareholders with a negative $851,000 of equity. Operating loss was $4.2m, operating cash burn was $4.0m, and liabilities stood at $5.2m while assets totalled $4.4m. The device itself-an investigational titanium disc designed to streamline diabetes management-remains unapproved by the FDA and is described on the company’s website as ‘an investigational device’ rather than a commercial product. (source: 10-Q, period ending 2026-03-31, SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1506983/000150101626018562/000150101626018562.htm)

The company’s latest SEC filing reads like two documents stitched together: one side boasts of a ‘capital-efficient, repeatable strategy concentrated public market access and an ai²-driven asset sourcing platform’ announced on 15 July 2026, while the other side quietly acknowledges a merger with Lōkahi Therapeutics that is structured as an all-stock transaction and positions the combined entity to execute a repeatable strategy. The proxy statement and annual report are hosted on a virtual shareholder meeting site and the company’s ethics code lives on the ‘Investors’ tab of its website, which is not the same as the code being embedded in the staff handbook. (source: DEF 14A, 2026-07-17, SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1506983/000149315226033763/formdef14a.htm)

Glucotrack’s core asset is the CBGM implant, a titanium disc intended to sit under the skin and stream glycaemic data to a phone for up to a year, eliminating the need for finger pricks. The product page calls it a ‘revolution in glycemic management’, yet the device is explicitly labelled ‘investigational’ and has not received FDA approval. The company’s most recent press release frames the Lōkahi Therapeutics merger as a move toward ‘capital-efficient, repeatable strategy’, but the arithmetic in the 10-Q shows $2.1m spent on R&D in the quarter, $9,000 on capital equipment, and a cash pile of $3.9m. Translation: the revolution will need to be bootstrapped on a budget that looks more ‘bootstrapped’ than ‘disruptive’. (source: CBGM Technology page, Glucotrack, https://glucotrack.com/cbgm-technology/; Press Release, 16 July 2026, Glucotrack, https://glucotrack.com/investor-relations/press-releases/)

The company’s SEC filings confirm that the annual report for the year ended 31 December 2025 is available at a virtual shareholder meeting URL, the proxy statement lives on the same site, and the ethics code is tucked behind the ‘Investors’ tab on glucotrack.com. None of these web locations is a substitute for hard numbers on a printed balance sheet, but they do illustrate how Glucotrack’s ‘future-facing’ narrative is currently hosted across more digital venues than physical assets. The filing index and company facts JSON on the SEC site confirm the completeness of the disclosures, yet they do not change the underlying arithmetic: negative equity, operating losses, and a device that is still investigational. (source: SEC EDGAR filing index for CIK 1506983, https://www.sec.gov/edgar/browse/?CIK=1506983; SEC company facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001506983.json)

What changed in the last 30 days? Glucotrack announced, filed, and then posted its March 2026 10-Q, and on 15 July 2026 it dropped an 8-K and a 425 Form disclosing the all-stock merger with Lōkahi Therapeutics. The proxy statement published on 17 July 2026 sets out the governance terms and virtual meeting details. The evidence does not include any revenue, EPS, cash flow positive quarters, regulatory approvals, or customer shipment data; the strongest disclosed figure remains the $4.3m net loss for Q1 2026. (source: 10-Q, 2026-03-31, SEC EDGAR; 8-K, 2026-07-15, SEC EDGAR; 425, 2026-07-15, SEC EDGAR; DEF 14A, 2026-07-17, SEC EDGAR)

The company’s product page and investor relations site are cleanly designed, but the gap between the visual promise and the filed arithmetic is wider than the titanium implant under the skin. The filings confirm every figure; the product page confirms every aspiration. Neither changes the fact that, as of 25 July 2026, Glucotrack’s balance sheet is thinner than the regulatory file on its investigational device. (source: CBGM Technology page, Glucotrack, https://glucotrack.com/cbgm-technology/; Press Releases, Glucotrack, https://glucotrack.com/investor-relations/press-releases/)